Radiation Therapy IS Indicated for Multifocal Breast Cancer After Breast-Conserving Surgery
Yes, radiation therapy is indicated for patients with multifocal breast cancer who undergo breast-conserving surgery, with whole-breast irradiation plus boost to each tumor bed being the standard approach. The ACOSOG Z11102 trial demonstrated that breast conservation with radiation is feasible in multifocal disease, achieving a 5-year local recurrence rate of only 3.1% 1.
Treatment Algorithm for Multifocal Disease
After Breast-Conserving Surgery:
- Whole-breast radiation is mandatory (Category 1 recommendation for node-positive, Category 2A for node-negative) 2
- Deliver 45-50 Gy in 23-25 fractions OR 40-42.5 Gy in 15-16 fractions (hypofractionation preferred) 3
- Boost to EACH tumor bed is required: 10-16 Gy at 2 Gy per fraction 3, 1
- Use CT-based treatment planning to minimize cardiac and pulmonary exposure 3
Regional Nodal Irradiation Criteria:
Add regional nodal radiation if:
- ≥4 positive lymph nodes (Category 1) 4
- 1-3 positive lymph nodes (strongly consider, Category 2A) 4
- High-risk node-negative disease with extensive lymphovascular invasion 4
The MA.20 trial showed regional nodal irradiation reduces locoregional recurrence (HR 0.59) and improves disease-free survival (HR 0.68) 3.
Critical Distinctions
Multifocal vs. Multicentric: While historically both were considered contraindications to breast conservation, contemporary evidence supports radiation after breast-conserving surgery for multifocal disease (multiple foci in same quadrant). The Z11102 trial specifically enrolled patients with 2-3 ipsilateral foci and demonstrated 83% successfully completed radiation without requiring mastectomy 1.
Key caveat: Multicentric disease (foci in different quadrants) remains more challenging. If the disease cannot be incorporated through a single incision with negative margins and acceptable cosmesis, mastectomy is preferred 2.
Absolute Contraindications to Breast Conservation with Radiation:
- Prior radiation to breast/chest wall
- Pregnancy requiring radiation during gestation
- Diffuse malignant microcalcifications
- Positive margins after re-excision attempts
- Widespread disease not excisable through single incision 2
Practical Considerations
Boost volume matters: The Z11102 trial found higher absolute boost volumes increased grade ≥2 dermatitis (OR 1.21), but did not worsen cosmetic outcomes 1. Each tumor bed requires individual boost treatment.
After neoadjuvant therapy: Base radiation decisions on pre-treatment staging, not post-chemotherapy pathology. If initially node-positive or locally advanced, radiation remains indicated even with pathologic complete response 4, 5.
Accelerated partial breast irradiation (APBI) is NOT appropriate for multifocal disease. APBI is only suitable for unifocal, stage I, ER-positive cancers in women ≥60 years 3.
Evidence Strength
The recommendation is based on NCCN Category 1 evidence for whole-breast radiation after lumpectomy in node-positive disease 2, supported by the prospective Z11102 trial specifically addressing multifocal presentation 1. Recent meta-analyses of 15,703 patients show no survival difference between mastectomy and breast conservation with radiation when appropriately delivered, though local recurrence is slightly higher (5.6% vs 4.2%) 6.
Bottom line: Multifocal breast cancer is no longer an automatic indication for mastectomy. With proper patient selection, complete excision of all foci with negative margins, and comprehensive radiation including boost to each tumor bed, breast conservation achieves excellent local control comparable to unifocal disease.